Graybug Vision Appoints Leading Ophthalmologists and Retinal Experts to Join Its Scientific Advisory Board
August 03, 2020 07:30 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (“Graybug”), a clinical stage biopharmaceutical company focused on developing transformative medicines to treat chronic...
CalciMedica and EpiPharma Enter into Research Collaboration to Discover and Develop CRAC Channel Inhibitor Therapies
July 21, 2020 08:00 ET
|
CalciMedica; EpiPharma LLC
Under the terms of the research collaboration agreement, CalciMedica will use EpiPharma’s state of the art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate its drug...
CalciMedica Announces Data Showing Auxora™ Substantially Improved Outcomes in Patients with Severe COVID-19 Pneumonia
July 16, 2020 08:00 ET
|
CalciMedica
Median time to recovery was more than two times faster for patients treated with Auxora plus standard of care compared to standard of care aloneThe percentage of patients requiring invasive mechanical...
UPDATE - CalciMedica Appoints Robert N. Wilson as Co-Chairman of the Board of Directors and Eric W. Roberts as Vice Chairman
June 02, 2020 15:57 ET
|
CalciMedica
Robert N. Wilson was Former Johnson & Johnson Vice ChairmanBoard Member, Eric W. Roberts, named Vice Chairman and Chairman of the Strategic Transactions and Finance Committee of the Board LA...
CalciMedica Announces Positive Topline Data from Interim Analysis of Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia
May 28, 2020 08:00 ET
|
CalciMedica
Interim results showed Auxora plus standard of care improved time to recovery and reduced ventilator use in patients compared to standard of care alone LA JOLLA, Calif., May 28, 2020 (GLOBE...
CalciMedica Raises $15 Million in Series C Financing Round Led by Valence Life Sciences
May 22, 2020 08:00 ET
|
CalciMedica
Funds to support ongoing clinical trials in patients with COVID-19 pneumonia and commercial manufacturing of Auxora™ LA JOLLA, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- CalciMedica Inc....
CalciMedica Announces that FDA Has Strongly Recommended Moving to a Blinded Placebo-controlled Trial with Auxora™ in Patients with Severe COVID-19 Pneumonia
May 21, 2020 08:00 ET
|
CalciMedica
LA JOLLA, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC)...
Graybug Vision Appoints Parisa Zamiri, Physician-Scientist with Deep Expertise in Ophthalmology, as Chief Medical Officer
May 18, 2020 07:30 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., May 18, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc., a clinical stage biopharmaceutical company focused on developing transformative medicines to treat vision-threatening...
CalciMedica Announces Independent Safety Review Committee Recommendation to Continue Phase 2 Study of CM4620-IE in Patients with Severe COVID-19 Pneumonia on Low-Flow Oxygen Therapy
May 07, 2020 08:00 ET
|
CalciMedica
LA JOLLA, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC)...
CalciMedica Expands Clinical Study to Assess CM4620-IE in Patients with Critical COVID-19 Pneumonia on High-Flow Oxygen Therapy
April 30, 2020 08:00 ET
|
CalciMedica
Phase 2 open-label study expands to additional sites across the U.S. and aims to enroll 120 patients LA JOLLA, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the...